Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway

Wen Jie Zhang, Walter Koltun, Anna F. Tilberg, Jennifer L. Thompson, Michael J. Chorney

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The interleukin (IL)-4-induced Stat6 signaling pathway is active in a variety of cell types, including immune cells and cancer cells, and plays an important tole in the regulation of gene expression, such as CD23 and major histocompatibility complex class II. Using a semiquantitative gel shift assay in which nuclear Stat6 activities were scored, three Stat6 activation phenotypes were defined as Stat6high (intense banding), Stat6low (medium intensity banding), and Stat6null (very low to no discernible banding). These Stat6 phenotypes correlated well with levels of CD23 expression, but not with those of human leukocyte antigen-DR cell-surface display. Pedigree analyses revealed a Mendelian inheritance pattern that can be explained by two STAT6 Pathway (STAT6P) activation genotypes, which we term A and a, where STAT6P*A determines an active Stat6 signaling and STAT6P*a determines an inactive Stat6 signaling, with incomplete dominance. Total Stat6 protein levels failed to correlate with the above Stat6 phenotypes allowing us to propose that IL-4-induced Stat6 signaling is a polygenic quantitative trait regulated by a collection of several contributing genetic loci that functionally interact. The Stat6null phenotype may result from a defect in Stat6 signaling, which has important implications with respect to the pathogenesis of cancer and Th1/Th2 cytokine imbalance in autoimmune diseases in general.

Original languageEnglish (US)
Pages (from-to)402-415
Number of pages14
JournalHuman Immunology
Volume64
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

STAT6 Transcription Factor
Interleukin-4
Phenotype
Multifactorial Inheritance
Inheritance Patterns
Genetic Loci
Gene Expression Regulation
Pedigree
HLA Antigens
Major Histocompatibility Complex
Autoimmune Diseases
Neoplasms
Gels
Genotype
Cytokines
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Zhang, Wen Jie ; Koltun, Walter ; Tilberg, Anna F. ; Thompson, Jennifer L. ; Chorney, Michael J. / Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway. In: Human Immunology. 2003 ; Vol. 64, No. 4. pp. 402-415.
@article{638140ac48214ed3ad93882fcce942cc,
title = "Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway",
abstract = "The interleukin (IL)-4-induced Stat6 signaling pathway is active in a variety of cell types, including immune cells and cancer cells, and plays an important tole in the regulation of gene expression, such as CD23 and major histocompatibility complex class II. Using a semiquantitative gel shift assay in which nuclear Stat6 activities were scored, three Stat6 activation phenotypes were defined as Stat6high (intense banding), Stat6low (medium intensity banding), and Stat6null (very low to no discernible banding). These Stat6 phenotypes correlated well with levels of CD23 expression, but not with those of human leukocyte antigen-DR cell-surface display. Pedigree analyses revealed a Mendelian inheritance pattern that can be explained by two STAT6 Pathway (STAT6P) activation genotypes, which we term A and a, where STAT6P*A determines an active Stat6 signaling and STAT6P*a determines an inactive Stat6 signaling, with incomplete dominance. Total Stat6 protein levels failed to correlate with the above Stat6 phenotypes allowing us to propose that IL-4-induced Stat6 signaling is a polygenic quantitative trait regulated by a collection of several contributing genetic loci that functionally interact. The Stat6null phenotype may result from a defect in Stat6 signaling, which has important implications with respect to the pathogenesis of cancer and Th1/Th2 cytokine imbalance in autoimmune diseases in general.",
author = "Zhang, {Wen Jie} and Walter Koltun and Tilberg, {Anna F.} and Thompson, {Jennifer L.} and Chorney, {Michael J.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0198-8859(03)00002-8",
language = "English (US)",
volume = "64",
pages = "402--415",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "4",

}

Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway. / Zhang, Wen Jie; Koltun, Walter; Tilberg, Anna F.; Thompson, Jennifer L.; Chorney, Michael J.

In: Human Immunology, Vol. 64, No. 4, 01.04.2003, p. 402-415.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway

AU - Zhang, Wen Jie

AU - Koltun, Walter

AU - Tilberg, Anna F.

AU - Thompson, Jennifer L.

AU - Chorney, Michael J.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - The interleukin (IL)-4-induced Stat6 signaling pathway is active in a variety of cell types, including immune cells and cancer cells, and plays an important tole in the regulation of gene expression, such as CD23 and major histocompatibility complex class II. Using a semiquantitative gel shift assay in which nuclear Stat6 activities were scored, three Stat6 activation phenotypes were defined as Stat6high (intense banding), Stat6low (medium intensity banding), and Stat6null (very low to no discernible banding). These Stat6 phenotypes correlated well with levels of CD23 expression, but not with those of human leukocyte antigen-DR cell-surface display. Pedigree analyses revealed a Mendelian inheritance pattern that can be explained by two STAT6 Pathway (STAT6P) activation genotypes, which we term A and a, where STAT6P*A determines an active Stat6 signaling and STAT6P*a determines an inactive Stat6 signaling, with incomplete dominance. Total Stat6 protein levels failed to correlate with the above Stat6 phenotypes allowing us to propose that IL-4-induced Stat6 signaling is a polygenic quantitative trait regulated by a collection of several contributing genetic loci that functionally interact. The Stat6null phenotype may result from a defect in Stat6 signaling, which has important implications with respect to the pathogenesis of cancer and Th1/Th2 cytokine imbalance in autoimmune diseases in general.

AB - The interleukin (IL)-4-induced Stat6 signaling pathway is active in a variety of cell types, including immune cells and cancer cells, and plays an important tole in the regulation of gene expression, such as CD23 and major histocompatibility complex class II. Using a semiquantitative gel shift assay in which nuclear Stat6 activities were scored, three Stat6 activation phenotypes were defined as Stat6high (intense banding), Stat6low (medium intensity banding), and Stat6null (very low to no discernible banding). These Stat6 phenotypes correlated well with levels of CD23 expression, but not with those of human leukocyte antigen-DR cell-surface display. Pedigree analyses revealed a Mendelian inheritance pattern that can be explained by two STAT6 Pathway (STAT6P) activation genotypes, which we term A and a, where STAT6P*A determines an active Stat6 signaling and STAT6P*a determines an inactive Stat6 signaling, with incomplete dominance. Total Stat6 protein levels failed to correlate with the above Stat6 phenotypes allowing us to propose that IL-4-induced Stat6 signaling is a polygenic quantitative trait regulated by a collection of several contributing genetic loci that functionally interact. The Stat6null phenotype may result from a defect in Stat6 signaling, which has important implications with respect to the pathogenesis of cancer and Th1/Th2 cytokine imbalance in autoimmune diseases in general.

UR - http://www.scopus.com/inward/record.url?scp=0037379876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037379876&partnerID=8YFLogxK

U2 - 10.1016/S0198-8859(03)00002-8

DO - 10.1016/S0198-8859(03)00002-8

M3 - Article

C2 - 12651067

AN - SCOPUS:0037379876

VL - 64

SP - 402

EP - 415

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 4

ER -